Literature DB >> 10752529

Complement activation products in the urine from proteinuric patients.

Yoshiki Morita1, Hiroshi Ikeguchi1, Jiro Nakamura1, Nigishi Hotta1, Yukio Yuzawa1, Seiichi Matsuo1.   

Abstract

The presence of plasma proteins in the tubular lumen has variety of adverse effects on the tubular cells. Among various plasma proteins filtered through glomerular barrier, complement has been proven as the possible candidate inducing tubulointerstitial injury. To study the role of intratubular complement activation in proteinuric patients, complement activation products (CAP) at C3 level (iC3b and Bb) and C9 level (membrane attack complex) were measured in both plasma and urine of patients with minimal change nephrotic syndrome (MCNS), focal glomerular sclerosis, IgA nephropathy, membranous nephropathy, and diabetic nephropathy. For evaluation of the effect of metabolic acidosis on the intratubular complement activation, urinary CAP were measured before and after sodium bicarbonate administration in patients with renal insufficiency. The following results were obtained: (1) Patients with focal glomerular sclerosis and diabetic nephropathy showed the highest level of urinary CAP excretion rate (unit/creatinine), while MCNS revealed no increase. (2) Patients with membranous nephropathy showed a unique finding, i.e., isolated increase of membrane attack complex excretion. (3) There was no significant correlation between urine and plasma levels of CAP. (4) Except for MCNS patients, the urinary excretion rate of CAP significantly increased when the level of proteinuria exceeded the nephrotic range, and it was significantly correlated with the serum creatinine level. (5) Urinary CAP excretion rate significantly decreased 2 wk after sodium bicarbonate administration without affecting the level of proteinuria or plasma CAP. These results suggest that the degree of intratubular complement activation correlates with the level of proteinuria, type of glomerular disease, impairment of renal function, and metabolic acidosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752529     DOI: 10.1681/ASN.V114700

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  50 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

Review 2.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

3.  Leaked protein and interstitial damage in the kidney: is complement the missing link?

Authors:  N S Sheerin; S H Sacks
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 4.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

5.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

6.  C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.

Authors:  Runhong Han; Shuai Hu; Weisong Qin; Jinsong Shi; Qin Hou; Xia Wang; Xiaodong Xu; Minchao Zhang; Caihong Zeng; Zhihong Liu; Hao Bao
Journal:  JCI Insight       Date:  2019-04-04

7.  The role of bicarbonate in CKD: evidence bulks up.

Authors:  Eric E Simon; L Lee Hamm
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 8.237

8.  Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.

Authors:  Shen-Ju Gou; Jun Yuan; Chen Wang; Ming-Hui Zhao; Min Chen
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

Review 9.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

Review 10.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.